AZNAstraZenecaRunning, no new patients
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
Advanced or Recurrent Endometrial Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 45 (final count)
- Started
- Dec 30, 2024
- Main results expected
- Nov 30, 2028
- Fully finished
- Nov 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of patients with Adverse Events
Measured over: Time from enrollment up to at least 90 days after last dose of study treatment
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06746116 · record last updated 2026-07-17 · checked 2026-11-09 15:47 UTC